



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

control number.			Complete if Known		
Substitute for form 1449A/PTO			Application Number	10/777,542	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Filing Date	February 12, 2004	
			First Named Inventor	Unchalee Kositprapa	
			Art Unit		
			Examiner Name		
Sheet	1	of	5	Attorney Docket Number	141-446

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number- Kind Code* (If known)			
/KW/	AA	us- 3,174,901	03-23-1965	Sterne	
/KW/	AB	us- 3,960,949	06-01-1976	Ahrens et al.	
/KW/	AC	us- 4,166,800	09-04-1979	Fong	
/KW/	AD	us- 4,389,330	06-21-1983	Tice et al.	
/KW/	AE	us- 4,687,777	08-18-1987	Meguro et al.	
/KW/	AF	us- 4,839,177	06-13-1989	Colombo et al.	
/KW/	AG	us- 4,891,223	01-02-1990	Ambegaonkar et al.	
/KW/	AH	us- 4,968,507	11-06-1990	Zentner et al.	
/KW/	AI	us- 5,294,770	03-15-1994	Riddle et al.	
/KW/	AJ	us- 5,356,913	10-18-1994	Colca	
/KW/	AK	us- 5,376,771	12-27-1994	Roy	
/KW/	AL	us- 5,478,852	12-26-1995	Olefsky et al.	
/KW/	AM	us- 5,602,133	02-11-1997	Antonucci et al.	
/KW/	AN	us- 5,658,474	08-19-1997	Geerke	
/KW/	AO	us- 5,681,584	10-28-1997	Savastano et al.	
/KW/	AP	us- 5,698,220	12-16-1997	Cardinal et al.	
/KW/	AO	us- 5,719,188	02-17-1998	Colca	
/KW/	AR	us- 5,859,037	01-12-1999	Whitcomb	
/KW/	AS	us- 5,916,584	06-29-1999	O'Donoghue et al.	
/KW/	AT	us- 5,952,356	09-14-1999	Ikeda et al.	

[illegible]

Examiner Signature	/Kevin Weddington/ (06/06/2007)	Date Considered	
--------------------	---------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

performance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Time will vary depending upon the needs of the individual case.

English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/777,542
		Filing Date	February 12, 2004
		First Named Inventor	Unchalee Kositprapa
		Art Unit	
		Examiner Name	
Sheet 2	of 5	Attorney Docket Number	141-446

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
/KW/	AU	US- 5,955,106	09-21-1999	Moeckel et al.	
/KW/	AV	US- 6,011,049	01-04-2000	Whitcomb	
/KW/	AW	US- 6,031,004	02-29-2000	Timmins et al.	
/KW/	AX	US- 6,099,859	08-08-2000	Cheng et al.	
/KW/	AY	US- 6,153,632	11-28-2000	Rieveley	
/KW/	AZ	US- 6,191,162	02-20-2001	Byrd et al.	
/KW/	BA	US- 6,248,363	06-19-2001	Patel et al.	
/KW/	BB	US- 6,291,495	09-18-2001	Rieveley	
/KW/	BC	US- 6,296,874	10-02-2001	Cutie et al.	
/KW/	BD	US- 6,329,403	12-11-2001	Odaka et al.	
/KW/	BE	US- 6,383,471	05-07-2002	Chen et al.	
/KW/	BF	US- 6,403,121	06-11-2002	Adjei et al.	
/KW/	BG	US- 6,451,342	09-17-2002	Adjei et al.	
/KW/	BH	US- 6,475,521	11-05-2002	Timmins et al.	
/KW/	BI	US- 6,524,621	02-25-2003	Adjei et al.	
/KW/	BJ	US- 6,599,284	07-29-2003	Faour	
/KW/	BK	US- 2002/0071866	06-13-2002	Geerke	
/KW/	BL	US- 2003/0113371	06-19-2003	Dhawan et al.	
/KW/	BM	US- 2003/0118647	06-26-2003	Seth	
/KW/	BN	US- 2003/011864	06-26-2003	Gao et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/KW/	CA	WO 96/09823	04-04-1996	Luo et al.		
/KW/	CB	WO 98/11879	03-26-1998	Shell et al.		
/KW/	CC	WO 98/55107	12-10-1998	Shell et al.		
/KW/	CD	WO 99/47128	09-23-1999	Timmins et al.		
/KW/	CE	WO 99/55320	11-04-1999	Nishii et al.		
/KW/	CF	WO 00/28989	05-25-2000	Lewis et al.		
/KW/	CG	WO 00/72827	12-07-2000	Straub et al.		
/KW/	CH	WO 01/35940	05-25-2001	Lewis et al.		
/KW/	CI	WO 01/35941	05-25-2001	Lilliot et al.		
/KW/	CJ	WO 01/82875	11-08-2001	Cutie et al.		

Examiner Signature	/Kevin Weddington/ (06/06/2007)	Date Considered	
-----------------------	---------------------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subtitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/777,542
		Filing Date	February 12, 2004
		First Named Inventor	Unchalee Kositprapa
		Art Unit	
		Examiner Name	
		Attorney Docket Number	141-446
Sheet	3	of	5

[illegible]

FOREIGN PATENT DOCUMENTS					Page	
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/KW	CK	WO 02/28181	04-11-2002	Gidwani et al.		
/KW	CL	WO 03/004009	01-16-2003	Matharu et al.		
/KW	CM	WO 03/035029	05-01-2003	Louie-Helm et al.		
/KW	CN	WO 03/047529	06-12-2003	Seth et al.		
/KW	CO	EP 0 169 105	01-22-1986	Zentner et al.		
/KW	CP	EP 0 283 369	09-21-1988	Wiernsperger et al.		
/KW	CO	EP 0 381 181	08-08-1995	Wenzel et al.		
/KW	CR	EP 0 749 751	12-27-1996	Ikeda et al.		
/KW	CS	EP 0 753 298	11-21-2001	Tsujiita et al.		
/KW	CT	EP 0 781 129	07-02-1997	Moeckel et al.		

Examiner Signature	/Kevin Waddington/ (06/06/2007)	Date Considered	
--------------------	---------------------------------	-----------------	--

Signature Kevin Weddington (11/16/2017)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

USPTO Patent Examination Documents at www.uspto.gov or MPEP

performance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Time will vary depending upon the needs of the individual case.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/777,542
		Filing Date	February 12, 2004
		First Named Inventor	Unchalee Kositprapa
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	141-446
Sheet 4	of 5		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/KW/	DA	P. Karttunen et al., International Journal of Clinical Pharmacology, Therapy and Toxicology, "The pharmacokinetics of metformin: a comparison of the properties of a rapid release and a sustained-release preparation" Vol. 21, No. 1 - 1983, pp. 31-36.	
/KW/	DB	P.J. Pentikainen, International Journal of Clinical Pharmacology, Therapy and Toxicology, "Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained-release products", Vol. 24, No. 4 - 1986, pp. 213-220.	
/KW/	DC	Finnish Monograph of the Diformin®, Retard tablet, with English translation	
/KW/	DD	O.J. Lucis, MD, Ph.D., MSC, Canada Medical Association J. Pharmacologic Update "The status of metformin in Canada" Vol. 128, January 1, 1983, pgs. 24-26.	
/KW/	DE	G. Belcher and D.R. Matthews, Experiment and Clinical Endocrinology & Diabetes, "Safety and tolerability of pioglitazone" Suppl. 2 (2000) pgs. 267-273.	
/KW/	DF	Daniel Einhorn, MD et al., Clinical Therapeutics "Pioglitazone Hydrochloride in Combination with Metformin in the Treatment of Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Study", Vol. 22, No. 12, 2000 pgs. 1395-1413.	
/KW/	DG	National Institute for Clinical Excellence Technology Appraisal Guidance - No. 21, "Guidance on the Use of Pioglitazone for Type 2 Diabetes Mellitus" March 2001, pgs. 1-13.	
/KW/	DH	The Pharmaceutical Journal, Vol. 265, No. 7122, p. 710 November 11, 2000 Clinical (abstract only).	

Examiner Signature	/Kevin Weddington/ (06/06/2007)	Date Considered	
--------------------	---------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/777,542
		Filing Date	February 12, 2004
		First Named Inventor	Unchalee Kositprapa
		Group Art Unit	
		Examiner Name	
Sheet 5 of 5	Attorney Docket Number	141-446	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/KW/	DI	Product Labeling for Glucophage® XR (July 2002).	
/KW/	DJ	ADA Professional Section Member Supplement 0474 and 0503-506 (Poster) p. A110; A117	
/KW/	DK	Website www.findarticles.com, Clinician Reviews, "Insulin-Sensitizing Diabetes Agent" September 1999.	
/KW/	DL	ACTOS® product label, Physician's Desk Reference, 55th Edition, pp. 3171-3175	
/KW/	DM	Rote Liste No. 11081 the Medicament MEDIABET of Medice; GLUCOBAY of Bayer; and GLUCOTARD of Boehringer Mannheim, Chem.-Pharm. Fabrik Pütter GmbH & Co. KG, Kuhlweg 37-39 Iserlohn/Germany, Editio Cantor Verlag für Medizin und Naturwissenschaften GmbH, 1993.	
/KW/	DN	Abdallah et al., "Preparation and Evaluation of Metformin Hydrochloride Controlled-Release Tablets" STP Pharma 4(1) pp. 15-20, 1988.	

Examiner Signature	/Kevin Weddington/ (06/06/2007)	Date Considered	
--------------------	---------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

1

11

Complete if Known

Application Number	10/777,542
--------------------	------------

Filing Date	February 12, 2004
-------------	-------------------

First Named Inventor	Unchalee Kositprapa
----------------------	---------------------

Art Unit	1615
----------	------

Examiner Name	Not yet assigned
---------------	------------------

Attorney Docket Number	141-446
------------------------	---------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ²
		Country Code ³ Number ⁴ Kind Code ⁵ (# known)				
/KW/	CU	WO99/47125	04-12-2005	Conley et al.		
/KW/	CV	EP 1 588 708 A1	10-26-2005	Takeda Pharm Co		

**Examiner
Signature**

/Kevin Weddington/ (06/06/2007)

Date _____

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.